The global imatinib drug market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of chronic myelogenous leukemia and gastrointestinal stromal tumors, rising awareness about the benefits of imatinib therapy, and high cost-effectiveness ratio.
The global imatinib drug market is segmented on the basis of type into tablets and capsules; on the basis of application into chronic myelogenous leukemia and gastrointestinal stromal tumors; and on the basis of region into North America, Latin America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA). The North American region dominates in terms of revenue share in 2018 due to higher prevalence rates for chronic myelogenous leukemia in this region. However, APAC is expected to grow at a higher CAGR during the forecast period owing to increasing awareness about benefits associated with imatinib therapy among patients suffering from chronic myelogenous leukemia or gastrointestinal stromal tumors.
- The drug is used to treat chronic myeloid leukemia and gastrointestinal stromal tumors.
- The drug is also used to treat other cancers such as lung cancer, breast cancer, and prostate cancer.
- Imatinib has been approved for use in the United States since 2001 and in Europe since 2002.
- In the United States, imatinib is marketed under the trade name Gleevec by Novartis Pharmaceuticals Corporation while in Europe it is marketed under the trade name Glivec by Novartis AG or Aventis Pharma SNC (now Sanofi).
- Imatinib was developed by Novartis Pharmaceuticals Corporation.
Industry Growth Insights published a new data on “Imatinib Drug Market”. The research report is titled “Imatinib Drug Market research by Types (Tablets, Capsules), By Applications (Chronic myelogenous leukemia, Gastrointestinal stromal tumors, Others), By Players/Companies Novartis, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Cipla Inc., Apotex Inc., Mylan Pharms Inc.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Imatinib Drug Market Research Report
By Type
Tablets, Capsules
By Application
Chronic myelogenous leukemia, Gastrointestinal stromal tumors, Others
By Companies
Novartis, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Cipla Inc., Apotex Inc., Mylan Pharms Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Imatinib Drug Market Report Segments:
The global Imatinib Drug market is segmented on the basis of:
Types
Tablets, Capsules
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic myelogenous leukemia, Gastrointestinal stromal tumors, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Glenmark Pharmaceuticals Ltd.
- Sun Pharmaceuticals
- Actavis Generics
- Dr. Reddy's Laboratories
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Cipla Inc.
- Apotex Inc.
- Mylan Pharms Inc.
Highlights of The Imatinib Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablets
- Capsules
- By Application:
- Chronic myelogenous leukemia
- Gastrointestinal stromal tumors
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Imatinib Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Imatinib is a type of medication used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major players in the imatinib drug market are Novartis, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Cipla Inc., Apotex Inc., Mylan Pharms Inc..
The imatinib drug market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Imatinib Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Imatinib Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Imatinib Drug Market - Supply Chain
4.5. Global Imatinib Drug Market Forecast
4.5.1. Imatinib Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Imatinib Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Imatinib Drug Market Absolute $ Opportunity
5. Global Imatinib Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Imatinib Drug Market Size and Volume Forecast by Type
5.3.1. Tablets
5.3.2. Capsules
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Imatinib Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Imatinib Drug Market Size and Volume Forecast by Application
6.3.1. Chronic myelogenous leukemia
6.3.2. Gastrointestinal stromal tumors
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Imatinib Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Imatinib Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Imatinib Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Imatinib Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Imatinib Drug Demand Share Forecast, 2019-2026
9. North America Imatinib Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Imatinib Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Imatinib Drug Market Size and Volume Forecast by Application
9.4.1. Chronic myelogenous leukemia
9.4.2. Gastrointestinal stromal tumors
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Imatinib Drug Market Size and Volume Forecast by Type
9.7.1. Tablets
9.7.2. Capsules
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Imatinib Drug Demand Share Forecast, 2019-2026
10. Latin America Imatinib Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Imatinib Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Imatinib Drug Market Size and Volume Forecast by Application
10.4.1. Chronic myelogenous leukemia
10.4.2. Gastrointestinal stromal tumors
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Imatinib Drug Market Size and Volume Forecast by Type
10.7.1. Tablets
10.7.2. Capsules
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Imatinib Drug Demand Share Forecast, 2019-2026
11. Europe Imatinib Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Imatinib Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Imatinib Drug Market Size and Volume Forecast by Application
11.4.1. Chronic myelogenous leukemia
11.4.2. Gastrointestinal stromal tumors
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Imatinib Drug Market Size and Volume Forecast by Type
11.7.1. Tablets
11.7.2. Capsules
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Imatinib Drug Demand Share, 2019-2026
12. Asia Pacific Imatinib Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Imatinib Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Imatinib Drug Market Size and Volume Forecast by Application
12.4.1. Chronic myelogenous leukemia
12.4.2. Gastrointestinal stromal tumors
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Imatinib Drug Market Size and Volume Forecast by Type
12.7.1. Tablets
12.7.2. Capsules
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Imatinib Drug Demand Share, 2019-2026
13. Middle East & Africa Imatinib Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Imatinib Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Imatinib Drug Market Size and Volume Forecast by Application
13.4.1. Chronic myelogenous leukemia
13.4.2. Gastrointestinal stromal tumors
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Imatinib Drug Market Size and Volume Forecast by Type
13.7.1. Tablets
13.7.2. Capsules
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Imatinib Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Imatinib Drug Market: Market Share Analysis
14.2. Imatinib Drug Distributors and Customers
14.3. Imatinib Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Glenmark Pharmaceuticals Ltd.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sun Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Actavis Generics
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Dr. Reddy's Laboratories
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva Pharmaceutical Industries Ltd.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sanofi S.A.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Cipla Inc.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Apotex Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mylan Pharms Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
